Megesterol

Small molecule

Megesterol is one of 10 small molecule programs targeting Atypical Endometrial Hyperplasia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atypical Endometrial HyperplasiaActive, not recruiting

Atypical Endometrial HyperplasiaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Atypical Endometrial Hyperplasia

#DrugCompanyPhaseTrials

Prometrium

Crestor

1 3

Depo-Provera

Megace

5 5

Metformin or Insulin Treatment

FFudan University

Phase 3

1 6

Mirena

Bayer

Phase 2

1 7

Megace

Daewon Pharmaceutical Co., Ltd.

Phase 2

1 8

Micronized Progesterone

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Preclinical

1 9

Norethisterone Acetate

MMansoura University

Preclinical

1 10

Megesterol

ZZagazig University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atypical Endometrial Hyperplasia1 trial

LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia

Completed·ZZagazig University·Phase 2/3·NCT04385667·143 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Megesterol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Megesterol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Megesterol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zagazig University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: ZZagazig University

Megesterol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atypical Endometrial Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News